VTX-294

VTX-294 is a synthetic small-molecule benzazepine and an ultra-potent, highly selective agonist of human Toll-like receptor 8 (TLR8), developed as a next-generation innate immune agonist and candidate vaccine adjuvant. In human TLR-transfected HEK293 reporter cells, VTX-294 preferentially activates TLR8 over TLR7 by roughly two orders of magnitude, driving NF-κB–dependent signaling and robust induction of pro-inflammatory and immunoregulatory cytokines such as TNF, IL-1β, IL-6, IL-10, and IL-12p40, as well as chemokines including CCL3, CCL4, CCL2, and CXCL8.[1][3] In ex vivo studies, VTX-294 potently activates both newborn cord and adult peripheral blood leukocytes and monocyte-derived dendritic cells, upregulating HLA-DR and CD86 and generating more potent responses than benchmark TLR agonists MPLA (TLR4), R848 (TLR7/8), and CL075 (TLR8).[1][2] VTX-294 also shows synergistic activity with MPLA, markedly enhancing cytokine production, and is being explored primarily as a vaccine adjuvant, with potential relevance to early-life immunization strategies and oncology settings in the broader benzazepine TLR8 agonist program.[1][2][7]